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The use of β2-agonist therapy before hospital attendance
for severe asthma exacerbations: a post-hoc analysis
Mitesh Patel1,2,9, Janine Pilcher2,3,9, Robert J Hancox4,5, Davitt Sheahan6, Alison Pritchard2, Irene Braithwaite2,3, Dominick Shaw1,
Peter Black7,✠, Mark Weatherall3,8 and Richard Beasley2,3,8 for the SMART Study Group
BACKGROUND: Patterns of inhaled β2-agonist therapy use during severe asthma exacerbations before hospital attendance are
poorly understood.
AIMS: To assess β2-agonist use prior to hospital attendance.
METHODS: We undertook an exploratory post hoc analysis of data from a 6-month clinical trial of 303 patients randomised to
combination budesonide/formoterol inhaler according to a Single combination inhaler as Maintenance And Reliever Therapy
regimen (‘SMART’) or ﬁxed-dose budesonide/formoterol with salbutamol as reliever (‘Standard’). Patterns of β2-agonist use for
14 days before hospital attendance with a severe asthma exacerbation were determined by electronic monitoring of inhaler use.
RESULTS: There were 22 hospital attendances in 16 patients during the study. Seven and nine hospital attendances were eligible
for analysis in the SMART and Standard groups, respectively. In both regimens, β2-agonist use increased before hospital attendance,
with a median (range) maximum daily number of actuations of 14 (9 to 63) budesonide/formoterol in SMART and 46 (6 to 95)
salbutamol in Standard with 4 (0 to 10) budesonide/formoterol actuations on the day of maximal salbutamol use. There was delay
in obtaining medical review despite high β2-agonist use, in 9/16 patients. Different patterns of use were observed, including
repeated days of no inhaled corticosteroid despite marked salbutamol use, which occurred in 3/9 patients in the Standard group.
CONCLUSIONS: Delay in obtaining medical review in association with high β2-agonist use is common in patients before hospital
presentation with severe exacerbations of asthma. The SMART regimen reduced nonadherence with inhaled corticosteroid therapy
during severe exacerbations.
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INTRODUCTION
Observational studies report that overuse of inhaled β2-agonists in
a severe asthma attack is common and is associated with an
increased risk of a fatal outcome.1,2 Many mechanisms have been
proposed to account for this observation.3,4 Over-reliance on
β2-agonist therapy, and self-administration of high doses of
β2-agonist leading to delays in seeking medical assistance in a life-
threatening attack, are common behaviours reported in asthma
mortality surveys.1,2,4,5 In the recent United Kingdom National
Review of Asthma Deaths, 39% of patients had been prescribed
more than 12 short-acting reliever inhalers in the year before
death, and 4% had been prescribed more than 50 reliever inhalers.
During the ﬁnal attack of asthma, 45% died without seeking
medical assistance or before emergency care could be provided.5
In the setting of a severe asthma attack, high β2-agonist use
increases the risk of hypokalaemia6 and QTc prolongation,6 and it
may cause direct cardiac toxicity aggravated by hypoxia.7 The risk
of death may be greater with high-dose, poorly β2-selective,
potent agonists with high intrinsic activity such as isoprenaline
and fenoterol, which have been implicated in asthma mortality
epidemics.8,9 The association may also be noncausal, because high
β2-agonist use may be a marker of severe asthma that is poorly
responsive to bronchodilator therapy, and thereby a surrogate
marker for mortality risk.10
However, there are limited data on patterns of actual use of β2-
agonist inhalers by patients during severe exacerbations and in
particular life-threatening attacks that lead to hospital admission
or death. Studies to date rely on the information from general
practitioners (GPs), patient self-report or from the relatives or
friends of patients who have died from asthma.1,2,11,12 All of these
may provide inaccurate estimates of actual medication use.
We recently undertook a 6-month randomised controlled trial
(RCT) of combination budesonide/formoterol metered-dose inha-
ler (MDI) therapy when used as per the Single combination inhaler
as Maintenance And Reliever Therapy (SMART) regimen or as a
ﬁxed-dose treatment with salbutamol MDI as reliever (Standard
regimen).13,14 Data on the actual use of inhaled treatment were
measured by electronic monitoring of MDI use. The SMART
regimen reduced severe exacerbations requiring systemic corti-
costeroids and the number of episodes of β2-agonist overuse.
13
However, in both the treatment groups, in ~ 90% of occasions in
which patients overused their β2-agonist in excess of the level at
which their management plan advised to seek medical review, no
such review was obtained within the subsequent 48 h.
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To further investigate the patterns of β2-agonist use in the
setting of severe exacerbations, we undertook an exploratory
analysis of β2-agonist use in the 14 days leading up to
presentation to hospital with a severe exacerbation. Our main
hypotheses were that there would be extremely high β2-agonist
use recorded in most patients regardless of randomised regimen,
and that this would be associated with delay in obtaining medical
review.
MATERIALS AND METHODS
An exploratory post hoc analysis of data was undertaken from a 24-week
multicentre, prospective, open-label, RCT of the SMART versus Standard
regimens in asthma patients aged 16 to 65 years. Eligible patients had a
physician’s diagnosis of asthma, a current prescription for inhaled
corticosteroid (ICS) and at least one asthma exacerbation in the preceding
year. Patients who had high baseline reliever use were not excluded, and
there was no step-down in maintenance inhaled treatment on entry into
the study. Full details of the trial have been published.13,14 The Study
Protocol is available at http://www.mrinz.ac.nz/uploads/mrinz/SMART_
Protocol.pdf, and see the Supplementary Material for further details. All
patients provided written informed consent, and the New Zealand Multi-
Region Ethics Committee approved the study protocol (MEC/09/11/127).
There were 151 patients randomised to receive 200/6 μg budesonide/
formoterol via MDI (Vannair, AstraZeneca NZ Limited, Auckland, New
Zealand; this is the MDI formulation of Symbicort Turbuhaler), two
actuations twice daily as maintenance with extra doses for relief of
symptoms as per the SMART regimen (SMART group), and 152 patients
were randomised to receive 200/6 μg budesonide/formoterol via MDI, two
actuations twice daily as maintenance with salbutamol 100 μg via MDI
(Ventolin, GlaxoSmithKline NZ Limited, Auckland, New Zealand) for relief of
symptoms (Standard group). Five study visits occurred over 24 weeks. At
the ﬁrst visit, all participants had their inhaler technique checked and were
provided verbal instructions and written asthma self-management plans
corresponding to their randomised regimen.15,16 Patients who previously
had GP-prescribed prednisone for self-initiation during an exacerbation
were able to continue with this practice during the study. Patients who
self-initiated prednisone for asthma were advised to also seek medical
review. This analysis is restricted to patients with a severe exacerbation of
asthma that resulted in an acute presentation to a hospital Emergency
Department and/or admission to hospital during the study period.
Main outcomes
The main variables of interest were as follows:
1. Individual patient and median daily budesonide/formoterol use in the
SMART group and budesonide/formoterol and salbutamol use in the
Standard group, in the 14 days preceding hospital attendance with a
severe exacerbation.
2. Median maximum number of budesonide/formoterol actuations in a
24-h period in the SMART group and median maximum number of
salbutamol actuations in a 24-h period and median number of
budesonide/formoterol actuations on the day of maximum salbutamol
use in the Standard group.
Secondary outcomes
1. Proportion of patients in each treatment group who did not seek
medical review within 48 h despite exceeding the level of β2-agonist
use at which this was recommended by their self-management plans,
i.e., 412 actuations per 24 h of budesonide/formoterol in SMART
(48 actuations in addition to the four maintenance doses) and
416 actuations per 24 h of salbutamol in Standard.
2. Proportion of patients in each treatment group with ICS nonadherence,
deﬁned as no budesonide/formoterol actuations in a 24-h period.
3. First hospital-measured serum potassium and QTc interval in SMART
versus Standard groups.
4. Association between the ﬁrst serum potassium measurement and
budesonide/formoterol use for SMART or salbutamol use for Standard
patients in the 7 days and 24 h preceding the hospital attendance.
5. Self-reported reliever use as recorded in hospital medical records versus
electronic monitoring of medication use.
Electronic medication use data
Smartinhaler Tracker electronic monitors (Nexus6 Limited, Auckland, New
Zealand) were incorporated in all Vannair and Ventolin MDIs dispensed in
the study.17 These validated monitors are 99.7% accurate in recording MDI
actuations during bench testing,18 and they were used according to
detailed trial quality control procedures.19 Each MDI actuation resulted in a
date and time log, which was downloaded at the next study visit. Patients
were informed that their inhalers measured the total number of actuations
used and were unaware of the detailed capabilities of the monitor to
record patterns of use.
Actuation data on medication use for the fourteen 24-h periods before
the attendance time at hospital with a severe exacerbation were extracted
for each patient. Repeated hospital attendance within 7 days of the
preceding visit was counted as part of the same episode.20
Hospital attendance data
At each of the scheduled study visits, participants were asked whether they
had sought medical help or whether they had taken oral prednisone since
the last visit. All Emergency Department (ED) visits and hospital admissions
for asthma were veriﬁed by searches of the hospital databases where the
patient attended. Documentation on inhaler use, ﬁrst electrocardiogram
recordings and serum potassium measurements were recorded.
Statistical analysis
Data description for medication use patterns for the 14 days before
hospital attendance episodes was shown. Serum potassium measurements
and QTc intervals were compared between randomised groups by mixed
linear models, to take account of repeated measurements of some
patients. The strength of association between serum potassium and
medication use before the hospital attendance was shown by scatter-plots
supplemented by calculation of the product–moment correlation coefﬁ-
cients for the association.
SAS version 9.2 and Microsoft Excel 2010 were used.
RESULTS
There were 22 hospital attendances (10 SMART and 12 Standard)
in 16 patients (seven SMART and nine Standard; Figure 1). There
were ﬁve hospital admissions (three SMART, two Standard). The
baseline characteristics of the 16 patients are shown in Table 1.
In the run-up to the ﬁrst hospital attendance, two patients self-
initiated prednisone: one Standard (who subsequently had GP
review) and one SMART. Two patients (both Standard) were
prescribed prednisone by a GP (Figures 2 and 3). One patient in
the SMART group went to their GP and was then referred in to the
hospital that same day.
Electronic medication data set
One patient in the SMART group had three hospital attendances in
the 7 days following the ﬁrst hospital admission. One patient in
the Standard group had one hospital attendance within the 7 days
following the ﬁrst attendance. In another patient randomised to
Standard treatment who had two hospital attendances, there
were no recorded reliever use data before either episode, owing
to the use of nonstudy inhaled medication. Thus, electronic data
for seven SMART and nine Standard group episodes were
included in the analysis of medication use patterns (Figure 1).
There was no reported use of nonstudy inhaled asthma treatment
in any of the other patients before the ﬁrst hospital attendance.
There was no data loss owing to inhaler loss or malfunction. There
were no days on which dose dumping was observed, using the
previously deﬁned criteria.21
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Medication use before hospital attendance
The use of budesonide/formoterol in the SMART group and
salbutamol in the Standard group progressively increased 5 days
before hospital attendance, and it peaked in the 24 h preceding
attendance (Figure 4). The use of salbutamol increased around
10 days before hospital attendance, before reducing to a lower
level and then progressively increasing in the 5 days before
hospital attendance (Figure 4).
For the maximum number of inhaler actuations in a 24-h period,
the median(range) was 14(9 to 63) for budesonide/formoterol in
the SMART group and 46(6 to 95) for salbutamol in the Standard
group. On the day of maximum salbutamol use for each
presentation in the Standard group, the median(range) number
of budesonide/formoterol actuations was 4(0 to10).
The use of medication by individual patients showed distinct
patterns (Figures 2 and 3), which are not obvious from the
summary data shown in Figure 4. For the SMART regimen, the
daily number of doses of budesonide/formoterol was consistent
with the use of budesonide/formoterol as maintenance and
reliever therapy, although it is possible that in some patients
budesonide/formoterol was used according to an as-required
‘reliever’ regimen. For the Standard regimen, three predominant
patterns were observed:
1. Maintenance budesonide/formoterol use with salbutamol
‘reliever’ use consistent with the ‘Standard regimen’
(Figure 3a,d,i).
2. Poorly/nonadherent budesonide/formoterol maintenance use
and salbutamol ‘reliever’ use (Figure 3e,f,h).
3. Variable budesonide/formoterol use and variable salbutamol
use consistent with ‘budesonide/formoterol and/or salbutamol
reliever regimen’ (Figure 3b,c,g).
Delay in medical review in the setting of β2-agonist overuse
There were 3/7 patients in the SMART group (Figure 2d,f,g) and
6/9 patients in the Standard group (Figure 3d–i) who delayed
obtaining medical review as recommended in the self-
management plan in the setting of β2-agonist overuse in the
Hospital attendances (n =12)
Allocation
Eligible attendances
Hospital attendances
Randomised (n =303)
Allocated to standard (n =152)Allocated to SMART (n =151)
Excluded (n =3)
Hospital attendances analysed
(n =9)
Hospital attendances analysed
(n =7)
Excluded  (n =3)
Hospital attendances (n =10)
RCT participants
From 9 patients in total•
•
•
•
•
From 7 patients in total
Repeat admission
within 7 days
(n =3)
Repeat admission
within 7 days (n =1)
Use of non-study
drug medication (n =2)
Figure 1. Flow of participants through the study, showing those presenting to hospital who were eligible for analysis.
Table 1. Baseline characteristics of patients attending hospital for
severe asthma
Characteristic SMART group
(n= 7)
Standard group
(n=9)
Age, years 46.9 (16.0) 43.3 (14.8)
Male gender 3 (43%) 2 (22%)
Ethnicity
European 6 (86%) 7 (78%)
Māori 0 (0%) 2 (22%)
Paciﬁc Islander 1 (14%) 0 (0%)
ACQ-7 score 1.98 (1.19) 3.10 (1.52)
On-treatment FEV1, litres 2.52 (0.82) 1.93 (1.02)
On-treatment FEV1, % predicted 80.2 (22.6) 62.7 (23.8)
Severe exacerbations in the
prior 12 months
2.29 (1.60) 2.33 (1.41)
Zero severe exacerbations 0 (0%) 0 (0%)
One severe exacerbation 3 (43%) 2 (22%)
Two severe exacerbations 2 (29%) 3 (33%)
Three severe exacerbations 0 (0%) 1 (11%)
Four severe exacerbations 1 (14%) 2 (22%)
Five severe exacerbations 1 (14%) 1 (11%)
Number of patients with at least
one prior hospital admission ever
for asthma
1 (14%) 5 (56%)
Duration of asthma, years 28.7 (20.0) 33.0 (15.3)
Data are mean (s.d.) or n (%). ACQ-7 is a composite score of asthma control,
comprising questions on asthma symptoms, rescue bronchodilator use
and forced expiratory volume in 1 s (FEV1) % predicted (overall scores
range from 0 to 6, with scores p 0.75 suggesting ‘well-controlled’ asthma
and scores ⩾ 1.50 suggesting ‘not well-controlled’ asthma).30,31 A severe
exacerbation was deﬁned as follows: (a) the use of systemic corticosteroids
for at least 3 days, or (b) a hospitalisation or Emergency Department visit
because of asthma, requiring systemic corticosteroids.20 Courses of
corticosteroids separated by 7 days or more were treated as separate
severe exacerbations.
Abbreviation: SMART, Single combination inhaler as Maintenance And
Reliever Therapy.
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Figure 2. Individual patterns of daily budesonide/formoterol use in the 14 days before hospital attendance in the SMART group.
Hospital attendances owing to Emergency Department (ED) visit or hospital admission are speciﬁed for each participant. The x axis is days
preceding or following the ﬁrst hospital attendance (i.e., day − 1 refers to the 24 h before the ﬁrst hospital attendance, and day 1 refers to the
24 h following the ﬁrst hospital attendance). Data extraction was for fourteen 24-h periods before the attendance time at hospital. The y axis is
the number of actuations per 24 h. Dashed horizontal lines represent the thresholds of β2-agonist use per day above which
self-management plans recommend medical review (412 actuations of budesonide/formoterol per day for SMART patients). (d) The
participant self-initiated prednisone for asthma (40 mg per day for 4 days) on day − 4 (without subsequent medical review until hospital
attendance). (g) The participant had four hospital attendances, identiﬁed by the solid arrows (hospital admissions occurred for the ﬁrst
and last attendances; ED visits occurred for the second and third attendances). Before the ﬁrst ED visit, the participant who attended was seen
by their general practitioner (GP). The participant was prescribed prednisone (40mg per day for 7 days, followed by a weaning course over the
next 21 days).
β2-agonist use before hospital attendance
M Patel et al
4
npj Primary Care Respiratory Medicine (2015) 14099 © 2015 Primary Care Respiratory Society UK/Macmillan Publishers Limited
lead up to hospital attendance. One SMART patient (Figure 2d)
self-initiated a course of prednisone, in accordance with their self-
management plan, but without medical review.
ICS nonadherence
ICS nonadherence occurred in two SMART patients, on a single
day each (Figure 2a,b). Three Standard patients had repeated days
of ICS nonadherence, despite ongoing extreme salbutamol
overuse (Figure 3e,f,h).
Physiological and biochemical parameters
The physiological, serum potassium and QTc interval measure-
ments at hospital presentation were similar in both treatment
groups (Table 2). The lowest potassium value was 3.2 mmol/l (in
the Standard patient, in whom no reliever medication use data
were available owing to nonstudy medication use). All other
recorded potassium values were ⩾ 3.6 mmol/l. There was no
association between serum potassium and the total number of
budesonide/formoterol or salbutamol actuations in the 24 h or
7 days preceding initial hospital attendance for SMART and
Standard patients, respectively (Online Supplementary
Figure OS1). One patient (in the SMART group) who was
subsequently diagnosed with idiopathic hypertrophic cardiomyo-
pathy had a QTc interval of 456 ms; all other measured values
were o440 ms (Online Supplement).
Documented β2-agonist use in medical case notes
Self-reported β2-agonist use was documented in the medical
records in 11/22 of ED attendances and, when recorded, under-
estimated actual use as measured by electronic monitoring for
patients in both groups (Table 3).
DISCUSSION
Main ﬁndings
This analysis shows that patients commonly take very high doses
of inhaled β2-agonist therapy in the 2-week period leading up to a
hospital attendance with a severe exacerbation of asthma. β2-
agonist overuse was particularly observed in the Standard
regimen, in which the median maximum number of actuations
of salbutamol in a 24-h period was 46 with an additional median
number of four actuations of budesonide/formoterol, compared
with a median maximum 14 actuations of budesonide/formoterol
in a 24-h period in the SMART group. Delays in seeking medical
review in response to exceeding the β2-agonist level indicated in
their asthma self-management plan were observed in both
groups, more commonly in patients randomised to the Standard
regimen. Repeated days of ICS nonadherence, in which patients
took no budesonide/formoterol actuations, were observed in one-
third of the Standard patients in the 2 weeks before hospital
attendance, in contrast to the SMART regimen in which this
pattern did not occur.
Strengths and limitations of this study
We recognise that this study was not powered to determine the
statistical signiﬁcance of differences between the SMART and
Standard regimens, and it was limited by the relatively small
sample size, because only 16 of 303 patients attended the hospital
for a severe exacerbation of asthma during the trial. However, this
is balanced by our use of electronic monitoring to provide data on
actual patterns of medication use in the setting of severe asthma
in real-world patients, which, to our knowledge, is unique.
Unlike previous similar analyses, which have relied on patient
report,22 electronic monitoring provides accurate individual data
on actual medication use in the setting of a severe exacerbation,
and insight into patterns of behaviour in seeking medical review.
We did not collect data on lung function outside of study visits,
and thus we are unable to correlate the observed patterns of
medication use with peak expiratory ﬂow rates during severe
exacerbations. We did not extend this analysis to include urgent
GP or after-hours attendance, as this would have resulted in
inclusion of some presentations of uncertain severity or clinical
signiﬁcance.
Entry to the study required patients to have had at least one
asthma exacerbation in the preceding year and a current
prescription for an inhaled corticosteroid. Although it is uncertain
whether patterns of inhaler use and health-seeking behaviour
before hospital attendance would differ between this group and
other asthmatics with less severe asthma, recruitment of this
population has the advantage of generating results relevant to
those patients who are at a high risk of a future exacerbation.23
It is inherently difﬁcult to make comparisons between
formoterol and salbutamol in terms of levels of overuse, owing
to their different pharmacological properties, including duration of
bronchodilator action. In our study, we have used a 1:2 dose
bioequivalence (6 μg:200 μg) for formoterol to salbutamol,13 on
the basis of bronchodilator studies of repeat dosing in acute
asthma.24,25 The high-use thresholds were based on the dose
limits of β2-agonist use requiring medical review, as deﬁned in the
respective self-management plans.15,16
Interpretation of ﬁndings in relation to previously published work
For both regimens, the plots of average medication use show
increasing reliever use from around 5 days preceding the hospital
attendance, which is consistent with the self-reported reliever use
data at the time of severe asthma exacerbations presented by
Tattersﬁeld et al.22 In our study, the individual data on medication
use from the electronic monitoring provided greater detail of how
patients vary their reliever therapy during worsening asthma.
Patients randomised to SMART had patterns of use broadly
consistent with this regimen, although it is probable that some
were taking the budesonide/formoterol as a ‘reliever’ only. In
Standard regimen patients, three predominant patterns were
observed, two were consistent with the Standard regimen, one of
which was characterised by poor maintenance budesonide/
formoterol adherence, and the third pattern was consistent with
a salbutamol and/or budesonide/formoterol use only as a
‘reliever’.
We previously observed that patients randomised to the SMART
regimen had fewer days of nonadherence with ICS in the form of
budesonide/formoterol therapy compared with the Standard
regimen.13 The present analysis indicates that differences in ICS
nonadherence persist within the setting of a severe exacerbation
of asthma. In the SMART group, two patients were nonadherent
on one day each in the 2 weeks before presentation. One-third of
the patients in the Standard group had repeated days on which
they took no ICS therapy, despite concomitant extremely high
salbutamol use. One patient did not take any ICS throughout the
2-week period despite up to 37 salbutamol actuations per day;
another patient had a three-day period of non-ICS use despite up
to 46 salbutamol actuations per day; and a third patient had eight
days of no ICS use despite up to 30 salbutamol actuations on
these days. We propose that these episodes of nonadherence with
ICS therapy in the Standard regimen contribute to the progression
of severe asthma leading to hospital presentation. It is likely that
the SMART regimen prevented nonadherence to ICS therapy in
patients poorly adherent to maintenance treatment, because
these patients used their budesonide/formoterol inhaler ‘as
needed’ in response to symptoms, rather than as per the formal
SMART regimen.
We were concerned that the higher intrinsic activity of
formoterol compared with salbutamol could potentially lead to
β2-agonist use before hospital attendance
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greater hypokalaemic and cardiovascular effects.26,27 However,
patients in the SMART group did not have lower serum potassium
levels, presumably because of the markedly lower doses of
budesonide/formoterol taken compared with salbutamol. The
observation that only one patient had a serum potassium level
below the lower limit of the normal range, despite such high
β2-agonist doses, indicates that substantive tolerance to the
systemic β2 effects occurs.
28,29 Unfortunately, too few patients had
an electrocardiogram at presentation to hospital to investigate the
relative effects on QTc interval.
Documentation in hospital medical records under-reported the
extent of β2-agonist overuse leading up to the hospital presenta-
tion. This observation probably reﬂects both under-reporting by
patients and the lack of recognition of the importance of accurate
determination and documentation of this feature of the history by
the attending medical staff. The clinical importance of this is
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Figure 4. Median daily medication use in the 14 days before hospital attendance in the SMART (n= 7 attendances) (a) and Standard (n= 9
attendances) (b) groups. There is a 1:2 dose bioequivalence (6 μg:200 μg) for formoterol to salbutamol,13 on the basis of bronchodilator
studies of repeat dosing in acute asthma.24,25 Dashed lines represent the thresholds of β2-agonist use per day above which self-management
plans recommend medical review (48 actuations of budesonide/formoterol per day above the four maintenance actuations (i.e., a total of 12
actuations) for SMART patients and 416 actuations of salbutamol per day for Standard patients). The x axis is days preceding the hospital
attendance (i.e., day − 1 refers to the 24 h before hospital attendance). Data extraction was for the fourteen 24-h periods before the
attendance time at hospital for each patient. The y axis is the median number of actuations per 24 h. Error bars are the interquartile range
(IQR). For one patient in the Standard group, there were no data before day − 6, as this was the day of the ﬁrst study visit (randomisation visit).
Figure 3. Individual patterns of daily salbutamol and budesonide/formoterol use in the 14 days before hospital attendance in the Standard
group. Hospital attendances owing to Emergency Department (ED) visit or hospital admission are speciﬁed for each participant. The x axis is
days preceding or following the ﬁrst hospital attendance (i.e., day − 1 refers to the 24 h before the ﬁrst hospital attendance, day 1 refers to the
24 h following the ﬁrst hospital attendance). Data extraction was for fourteen 24-h periods before the attendance time at hospital. The y axis is
the number of actuations per 24 h. Horizontal dashed lines represent the thresholds of β2-agonist use per day above which self-management
plans recommend medical review (416 actuations of salbutamol per day for Standard patients). (d) The participant self-initiated prednisone
(40mg per day for 14 days) for asthma on day − 11 (with subsequent medical review by a general practitioner (GP) on day − 9).
(g) The participant was prescribed prednisone (40mg per day for 7 days) for asthma by a general practitioner on day − 9. (h) The participant
was prescribed prednisone (40mg per day for 4 days) for asthma by a general practitioner on day − 7. (i) The participant had two ED visits,
identiﬁed by the solid arrows, and there were no data before day − 6, as this was the day of the ﬁrst study visit (randomisation visit). The
participant was prescribed prednisone (40mg per day for 7 days). (c) and (f) refer to two episodes in the same participant, occurring
4 months apart.
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illustrated by the three patients, each of whom used at least 95
salbutamol actuations in the 48 h before attendance, and who
were subsequently discharged from the ED on the day of their
presentation. Our ﬁndings of very high doses of self-administered
β2-agonist, in the form of salbutamol or formoterol, are consistent
with a prior study demonstrating high blood salbutamol
concentrations in patients dying of asthma.11
Implications for future research, policy and practice
There was delay in obtaining medical review or initiating oral
prednisone despite high β2-agonist use above the predeﬁned
levels indicating the requirement for medical review and
intervention in half of the patients. This is likely to be an
underestimate of the frequency of delay in obtaining medical
review and intervention in clinical practice, as the patients were
closely followed up in the setting of the clinical trial with
implementation of personalised asthma management plans,
reinforced at regular clinic review. During periods of overuse,
the opportunity exists for patients to seek medical review and
receive appropriate medical intervention to reduce the risk of a
life-threatening attack. The importance of this behaviour is
underlined by the repeated ﬁndings from asthma mortality
surveys, which showed that marked overuse of β2-agonist drugs
and associated delay in seeking medical review are important
factors contributing to a fatal outcome.1–4 In the recent United
Kingdom National Review of Asthma Deaths, 39% of patients had
been prescribed more than 12 short-acting reliever inhalers in the
year before death, and 4% of the patients had been prescribed
more than 50 reliever inhalers. During the ﬁnal attack of asthma,
45% died without seeking medical assistance or before emer-
gency care could be provided.5
Nonadherence to maintenance ICS therapy before hospital
attendance was observed in the Standard group. The use of the
SMART regimen reduced nonadherence with ICS therapy, which
together with the increased self-administration of ICS therapy in
the setting of worsening asthma is likely to be responsible for the
reduction in severe exacerbations requiring oral corticosteroids
with its use.13
Conclusions
In conclusion, many patients take very high doses of inhaled
β2-agonists for prolonged periods before presentation to hospital
with severe asthma. During this period, the opportunity exists to
seek medical review and appropriate medical intervention to
reduce the risk of a life-threatening attack. The SMART regimen
led to reduced nonadherence with ICS therapy, which together
with the increased self-administration of ICS therapy in the setting
of worsening asthma is likely to be responsible for the reduction in
severe exacerbations requiring oral corticosteroids with its use.
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Table 3. Self-reported β2-agonist use in medical records versus
electronic monitoringa
Patient
codeb
Number of actuations
measured by electronic
monitor in the 24 h
preceding attendancec
Self-reported β2-agonist
use documented in
hospital medical records
SMART B 18 Using inhaler every 20min
SMART C 7 Using inhaler four times a
day
SMART F 39 Using inhaler every 30min
SMART Gd 42 Using multiple doses of own
medicine
Standard A 13 4 actuations of salbutamol
Standard B 3 12 puffs of salbutamol
Standard C 18 3 puffs of salbutamol in 2 h
Standard D 8 6 puffs of salbutamol every
1–2 h
Standard E 30 Salbutamol 20 times per day
Standard H 86 Increasing use of salbutamol
in the past 24 h
Standard Ie 25 Using salbutamol three
times per day
a4/10 and 7/12 of attendances in the Single combination inhaler as
Maintenance And Reliever Therapy (SMART) and Standard groups had self-
reported β2-agonist use documented in the hospital medical records.
bRefers to patient code on the ﬁgures displaying individual patient
patterns of use.
cNumber of budesonide/formoterol actuations for SMART and number of
salbutamol actuations for Standard.
dBefore the fourth attendance.
eBefore the ﬁrst attendance.
Table 2. Initial physiological and biochemical parameters for all
attendances to hospital for severe asthma
Parameter SMART group Standard group
Number of attendancesa 9 12
Number of ambulance transfers 2 5
Initial SpO2, % saturation
b 97.6 (1.3) 96.3 (4.0)
Initial respiratory rate, breaths/min 24.6 (3.6) 27.1 (7.9)
Initial heart rate, beats/min 100.8 (18.1) 95.5 (14.7)
Initial systolic blood pressure, mmHg 142.7 (18.5) 130.0 (17.9)
Initial diastolic blood pressure,
mmHg
87.0 (14.2) 83.2 (15.3)
Attendances with PEFR performed 4 (44%) 9 (75%)
PEFR, l/min 238.8 (80.3) 315.0 (128.0)
% Best value 59.2 (14.7) 72.3 (24.3)
Attendances with serum potassium
performed
9 (100%) 8 (67%)
Serum potassium, mmol/lc 4.13 (0.29) 3.76 (0.32)
Attendances with an ECG performed 7 (78%) 3 (25%)
QTc interval, msd 418.6 (21.3) 401.1 (11.0)
Values are mean (s.d.) or n (%). The comparison between randomised
groups used a mixed linear model to take account of repeated
measurements of some participants. Estimates may be numerically
different from the values calculated from the tabulated mean values.
Abbreviations: ECG, electrocardiogram; PEFR, peak expiratory ﬂow rate;
SMART, Single combination inhaler as Maintenance And Reliever Therapy;
SpO2, oxygen saturation by pulse oximetry.
an=Nine attendances for SMART as there were no clinical data recorded
for one patient who left the Emergency Department before clinical review.
bSpO2 was recorded on oxygen therapy for one SMART attendance and
three Standard attendances.
cSMART minus Standard mean (95% conﬁdence interval (CI))= 0.33 (−0.07
to 0.73), P= 0.093.
dSMART minus Standard mean (95% CI)= 22.2 (−21.6 to 65.9), P= 0.25.
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